Bleeding and myocardial infarction have a persistent fatal impact beyond one year in patients undergoing PCI, highlighting the importance of balancing ischemic and bleeding risks.
May support extended risk mitigation post-PCI; leaves open need for randomized trials to guide long-term strategies.
The fatal impact of bleeding and MI persisted beyond one year. Additional bleeding or MIs resulted in a poorer prognosis. De-escalation of antiplatelet therapy at the time of BARC 3 bleeding could have a major safety merit. These results emphasize the importance of considering the net clinical benefit including ischemic and bleeding events. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01813435.
No takes yet. Share an insight, caveat, or question.
Hara et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: